Our report suggests that APG-2449 may help to meet these needs by serving as (1) a novel ALK/ROS1 inhibitor that can overcome acquired drug resistance conferred by secondary mutations and other resistance mechanisms in ALK+/ROS1+ NSCLC; (2) a unique FAK inhibitor with a potentially different pharmacologic profile; and (3) an important constituent of combinations with SOC chemotherapeutics or targeted agents that can reverse primary or acquired drug resistance in FAK-overexpressing or amplified ovarian cancer and EGFR-mutant NSCLC models. This evidence concerns the gene PTK2 and ovarian carcinoma.